Navigation Links
Soflens Multi-Focal

ProductsSoflens Multi-Focal
Company Bausch & Lomb, Inc.
Item Soflens Multi-Focal
Features Easy to fit, easy to wear and easy to succeed. Exceptional vision at any distance. Visibility tint. Alternative to spectacles.
Description SofLens Multi-Focal with unique Natra-Sight Optics designed to provide broad transition for near, intermediate and far vision, SofLens Multi-Focal lenses offer crisp, clear vision at all distances.
Info Bausch & Lomb, Inc.
Customer Service: 585-338-6000
Web site: http://www.bausch.com/en_US/

Related medicine products :

1. Soflens66 Toric
2. Soflens one day disposable contact lenses
3. Soflens 59
4. Soflens 66
5. Multi-Focal ERG Electrodiagnostic System
...the rapid, detection of platelet dysfunction. It i... that uniquely simulates the in vivo function of p...s platelet function under high shear conditions si...lood vessel. Testing is performed using a small wh...
...rming erythrocyte sedimentation rate (ESR) tests u...es-matic System DIESSE brings to the clinical diag... which addresses and resolves every technical limi...e.,By means of a fully automated analyzer and a es...
...n rate analysers, which are especially user-friend...stablished advantages of the existing analysers wi...rantee time-saving standardised analysis of the er...s an essential aspect of daily recurrent routine a...
Blood sedimentation rate analysis
Medicine Products:
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...ve said that people should not unnecessarily panic...cancer. The study, which appears in the Journal of... it was most probably, children and the very elder...The researchers reviewed over 300 studies on the e...
...arned a doctor of Indian origin who refused to tre... he was an asylum seeker in Britain. Mahesh Chand...he man treatment because "he was not British and d...C committee has been told. Chandra, who studied ...
...manufactured TGN-1412, has now admitted that the d...onkeys. Four out of the six who were admitted to t...following the drug administration are recovering, ...ntroversial clinical trial had been conducted at N...
...ut whether sporadic outbreaks of bird flu could in...Although the impact of the H5N1 bird flu infection..., bird flu pandemic could claim a million lives, w...f the lethal viruses to infect birds. However, it ...
Other Medicine News:Health News:Drug Company Admits Knowledge Of Side Effects In Monkeys 2
(Date:10/13/2008)...om Multiple Cancer Populations Facilitates ...ich., Oct. 13 /- Rubicon Genomics, In...k to amplify DNA samples for The,Cancer Atlas Geno...lify and standardize total genomic,DNA from 3,000 ... Rubicon,GenomePlex(TM) Whole Genome Amplification...
(Date:10/12/2008)... thin struts designed for more uniform drug ... and WASHINGTON, Oct. 12 /-... announced comprehensive data from,the TAXUS ATLAS...,multi-center, single-arm, historically controlle...aclitaxel-Eluting Stent System in a variety of,les...
(Date:10/10/2008)...10 /- Diplomat Specialty,Pharmacy ann...iplomat,Specialty Pharmacy to be one of only three...herapy Optimization Study for Multiple Sclerosis (... is to examine the benefits of a,specialty pharmac...nce and,patient outcomes. Targeted patient outcome...
(Date:10/10/2008)...Newswire-FirstCall/ -- Boston Scientific,Corporati...he Company,s major,events and press announcements ...twentieth annual Transcatheter Cardiovascular Ther...om October 12 to 17 in Washington, D.C., Boston S...y and,efficacy data on its TAXUS(R) Express2(TM) a...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6Team finds an economical way to boost the vitamin A content of maize 1947 1Team finds an economical way to boost the vitamin A content of maize 1947 2Team finds an economical way to boost the vitamin A content of maize 1947 3Fleishman Hillard Names FFI Global Cause for 2008 9741 1Fleishman Hillard Names FFI Global Cause for 2008 9741 2Immune Therapy May Help Some Heart Failure Patients 9737 1Immune Therapy May Help Some Heart Failure Patients 9737 2Immune Therapy May Help Some Heart Failure Patients 9737 3Report Urges More Research Into Cell Phones 9734 1Report Urges More Research Into Cell Phones 9734 2Report Urges More Research Into Cell Phones 9734 3
...-FirstCall/ --,Pharmacyclics, Inc. announced today...e deacetylase (HDAC) inhibitor and,Bruton,s tyrosi...ill take place at the American Association for Can... April 14-18, 2007, at the Los,Angeles Convention ...ns are as follows:, Sunday, April 15, 2007, ...
...ence in Barcelona,Spain, VANCOUVER and SAN DIEGO,...IX Inc. , a clinical-stage developer,of drugs for ...ults,confirming the previously announced clinical ...clinical benefit, safety and,tolerability in a Pha...itor, celgosivir (MX-3253), in combination with pe...
Other Medicine Technology:Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 2Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8